12:13 PM EDT, 04/06/2026 (MT Newswires) -- All three major US stock indexes were edging higher in late-morning trading Monday as investors weighed prospects for a Middle East peace agreement.

Iran rejected a proposed temporary ceasefire and instead demanded a permanent end to the war as US President Donald Trump's deadline for the reopening of the Strait of Hormuz nears, news outlets reported.

In economic news, the Institute for Supply Management's US services index fell to a reading of 54.0 in March from 56.1 in February, compared with expectations for a smaller decrease to 54.9 in a Bloomberg survey. The index indicates a slower pace of expansion.

In company news, Soleno Therapeutics ( SLNO ) rose past 32% after Neurocrine Biosciences ( NBIX ) entered into a definitive agreement to acquire the company for $53 per share in cash, or a total of $2.9 billion. Neurocrine said the deal is expected to close within 90 days.

Tesla (TSLA) vehicles were cleared by the US National Highway Traffic Safety Administration, which said it closed a preliminary probe into crashes involving the "Actually Smart Summon" feature, citing low incident frequency and severity. Shares of the company fell 1.8%.

VinFast Auto ( VFS ) shares rose 3.7% after the company said it received more than 135,000 orders for electric scooters from dealers and shipped more than 93,000 e-scooters to dealers in Vietnam in March. The company said last month's performance marks "record growth."

Amgen ( AMGN ) said a phase 3 trial of a subcutaneous formulation of Tepezza, administered through an on-body injector, met its primary and key secondary endpoints in moderate-to-severe active thyroid eye disease. The shares were down 1%.

Netflix ( NFLX ) must reduce subscription fees and issue reimbursements after a Roman tribunal declared its historical rate increases illegitimate, Italian consumer association Movimento Consumatori said. The entertainment company plans to appeal the decision, Reuters reported. Netflix ( NFLX ) shares fell 0.6% in the session.

Biogen (BIIB) shares fell 1.4% after the company said in a regulatory filing that it expects to take a charge that will lower its Q1 GAAP and non-GAAP earnings by $0.19 per share. The charge is related to acquired in-process research and development, as well as upfront and milestone expenses.

Price: 52.23, Change: +12.74, Percent Change: +32.25